Compare GHRS & VMET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GHRS | VMET |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | Ireland | Canada |
| Employees | N/A | 8 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 947.2M | 1.1B |
| IPO Year | 2021 | N/A |
| Metric | GHRS | VMET |
|---|---|---|
| Price | $16.58 | $11.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $41.38 | N/A |
| AVG Volume (30 Days) | 140.6K | ★ 181.3K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $185.73 |
| Revenue Next Year | N/A | $6.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.66 | $9.10 |
| 52 Week High | $19.51 | $12.50 |
| Indicator | GHRS | VMET |
|---|---|---|
| Relative Strength Index (RSI) | 62.71 | 51.34 |
| Support Level | $12.34 | $9.14 |
| Resistance Level | $19.26 | N/A |
| Average True Range (ATR) | 0.81 | 0.58 |
| MACD | 0.33 | 0.22 |
| Stochastic Oscillator | 88.84 | 71.47 |
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Versamet Royalties Corp is a diversified metals royalty and streaming company with exposure to a range of resource royalties and streams including gold, silver, copper, zinc, graphite and uranium, across a variety of jurisdictions. The Company's operating segments are considered to be its individual royalties, streams and the Greenstone gold interest.